Jyong Biotech Ltd. (MENS)
- Previous Close
30.01 - Open
30.20 - Bid 27.44 x 100
- Ask 37.70 x 100
- Day's Range
26.40 - 30.71 - 52 Week Range
6.01 - 67.00 - Volume
28,926 - Avg. Volume
370,009 - Market Cap (intraday)
2.068B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.04 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Jyong Biotech Ltd., a science-driven biotechnology company, develops and commercializes plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.
jyongbio.comRecent News: MENS
View MorePerformance Overview: MENS
Trailing total returns as of 11/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Statistics: MENS
View MoreValuation Measures
Market Cap
2.07B
Enterprise Value
2.09B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-17.59%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-3.02M
Diluted EPS (ttm)
-0.04
Balance Sheet and Cash Flow
Total Cash (mrq)
98k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.73M
Compare To: MENS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.